Skip to main content

Table 2 Baseline characteristics and disease activity

From: Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial

 

Placebo (N = 105)

Baricitinib 2 mg (N = 105)

Baricitinib 4 mg (N = 104)

Age, years, mean (SD)

44.9 (12.8)

43.2 (11.0)

45.0 (12.4)

Female, n (%)

99 (94.3)

96 (91.4)

99 (95.2)

Time since onset of SLE symptoms, years, mean (SD)

9.7 (7.7)

11.8 (9.1)

11.5 (10.3)

SLEDAI-2K score, mean (SD)

8.9 (2.9)

8.8 (3.4)

9.0 (3.3)

≥1 A or ≥2 B BILAG scores, n (%)

62 (59.0)

56 (53.3)

69 (66.3)

Physician’s Global Assessment scorea, mean (SD)

1.5 (0.5)

1.5 (0.5)

1.6 (0.5)

Positive anti-dsDNA, n (%)

51 (48.6)

56 (53.3)

53 (51.0)

Anti-dsDNA, IU/mL, median (range)b

125.8 (33, 999)

139.8 (35, 1167)

128.4 (31, 1864)

Immunoglobulin G, g/L, median (range)c

13.4 (5.2–53.4)

13.5 (6.3–26.1)

13.0 (6.9–40.6)

Complement C3, g/L, median (range)

1.0 (0.3–1.7)

1.0 (0.4–1.7)

1.1 (0.26–2.0)

Complement C4, g/L, median (range)

0.2 (0.0–0.5)

0.2 (0.0–0.4)

0.2 (0.0–0.9)

  1. Data are presented as mean (standard deviation) unless stated otherwise
  2. a Scores range from 0 to 3 on a visual analogue scale with higher values indicating more severe disease
  3. b Reported for patients with anti-dsDNA ≥30 IU/mL at baseline
  4. c Placebo, n = 101; baricitinib 2 mg, n = 99; baricitinib 4 mg, n = 96)
  5. BILAG British Isles Lupus Assessment Group, C component, dsDNA double-stranded deoxyribonucleic acid, N number of patients, n number of patients in a subgroup, SLE systemic lupus erythematosus, SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index-2000
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us